Across TCGA pan-cancer cohorts, PIRT mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated PIRT data layer compared with 21 for mass-spec protein and 3 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher PIRT mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PIRT expression acts as an unfavorable survival marker.
GBM are the cancer types where PIRT mass-spec protein most reproducibly stratifies survival.